Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “buy” rating reaffirmed by investment analysts at Deutsche Bank AG in a report released on Wednesday. They presently have a $28.00 target price on the stock, down from their prior target price of $43.00. Deutsche Bank AG’s price objective would indicate a potential upside of 62.89% from the stock’s current price.
TEVA has been the topic of a number of other research reports. Credit Suisse Group set a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a report on Thursday, August 3rd. Cantor Fitzgerald set a $31.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Thursday, June 22nd. Vetr raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective on the stock in a report on Monday, July 24th. Zacks Investment Research raised shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, BidaskClub downgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating in a report on Tuesday. Three equities research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries Limited presently has a consensus rating of “Hold” and an average target price of $37.69.
Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 17.19 on Wednesday. The company’s market cap is $17.47 billion. The stock has a 50 day moving average of $30.08 and a 200 day moving average of $31.67. Teva Pharmaceutical Industries Limited has a 52-week low of $17.12 and a 52-week high of $55.39.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. The business had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the previous year, the business posted $1.25 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.39 EPS for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://stocknewstimes.com/2017/08/11/deutsche-bank-ag-reiterates-buy-rating-for-teva-pharmaceutical-industries-limited-nyseteva.html.
Large investors have recently made changes to their positions in the company. Teachers Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the fourth quarter valued at $21,946,000. Chevy Chase Trust Holdings Inc. raised its position in Teva Pharmaceutical Industries Limited by 3.4% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 6,273 shares of the company’s stock valued at $201,000 after buying an additional 207 shares during the last quarter. Manning & Napier Advisors LLC raised its position in Teva Pharmaceutical Industries Limited by 15.0% in the first quarter. Manning & Napier Advisors LLC now owns 96,678 shares of the company’s stock valued at $3,101,000 after buying an additional 12,645 shares during the last quarter. National Pension Service raised its position in Teva Pharmaceutical Industries Limited by 8.6% in the first quarter. National Pension Service now owns 732,038 shares of the company’s stock valued at $23,945,000 after buying an additional 57,726 shares during the last quarter. Finally, Bank of Montreal Can raised its position in Teva Pharmaceutical Industries Limited by 5.4% in the first quarter. Bank of Montreal Can now owns 638,426 shares of the company’s stock valued at $20,486,000 after buying an additional 32,960 shares during the last quarter. Institutional investors own 56.27% of the company’s stock.
Teva Pharmaceutical Industries Limited Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.
